Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
ZIMV.US
id: 1056
ZimVie (ZIMV) Failure to Meet 2022 Earnings Projections Case
- On March 2, 2023, $ZIMV fell 44% after the Company’s Q4’ 22 and full Y2022 earnings came in far below expectations.
- On it, $ZIMV fell 44.5%, losing $123M+ of shareholder value.
- Investors may have grounds to suspect ZimVie of business setbacks, which led to their losses.
ZimVie is a global life sciences leader in the dental and spine markets. In March 2022, the Company became an independent, publicly traded spin-off of the dental and spine business units of Zimmer Biomet.
On March 2, 2023, Company reported fourth quarter and full-year 2022 earnings that came in far below analysts’ expectations.
On this news, $ZIMV fell 44.5% and lost over $123 million of its market capitalization, seriously damaging shareholders.
Considering all the information, investors might have grounds to suspect ZimVie of failing to execute its financial plans, which led to their losses.
The case is already under investigation by at least one of the reputable law firms.
Case Status
Inactive Investigation
Alleged Offence
Misleading Statements,
Failure to Disclose,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
03/02/2023